Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

2.215 -0.075 (-3.28%)

Streaming Delayed Price Updated: 9:50 AM EDT, Aug 31, 2026 Add to My Watchlist

Price and Volume

Volume	122,875
Open	2.270
Bid (Size)	2.210 (3,100)
Ask (Size)	2.220 (1,700)
Prev. Close	2.290
Today's Range	2.215 - 2.290
52wk Range	1.030 - 2.680
Shares Outstanding	144,474,452
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Today 8:30 EDT

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

August 24, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+94.3%	+94.3%
1 Month	-4.1%	-4.1%
3 Month	+7.0%	+7.0%
6 Month	+42.0%	+42.0%
1 Year	+97.8%	+97.8%

More News

Lexicon (LXRX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Lexicon Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses Estimates ↗

August 06, 2026

Via Chartmill

Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally ↗

July 08, 2026

Via Chartmill

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

August 06, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

July 27, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗

June 11, 2026

Via The Motley Fool

Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss ↗

May 07, 2026

Via Chartmill

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Beats Q4 Estimates and Strengthens Cash Runway ↗

March 05, 2026

Via Chartmill

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

June 03, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon (LXRX) Q1 2026 Earnings Transcript ↗

June 01, 2026

Via The Motley Fool

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

May 07, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

May 04, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

April 17, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

March 24, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

March 23, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

March 11, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon (LXRX) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Via The Motley Fool

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?

Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market

What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?

The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 2.215

When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 08/31/26 09:50 AM ET

What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 320.01M

How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?

Lexicon Pharmaceuticals, Inc. - Common Stock has 320M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.